This study suggests that naringenin (NAR) and oleuropein (OLE) may exert antiproliferative and regulatory effects in prostate cancer cells, and that this may be regulated by modulating miR-155-5p-mediated KRAS/CDK2 targets. Here, KRAS is linked to prostate carcinoma.